Both in Biotechnology
Beam Therapeutics vs Tarsus Pharmaceuticals
Over the past year BEAM returned +12.3% and TARS returned +7.3%; their daily moves had a correlation of 0.32.
BEAM +12.3% TARS +7.3%Growth of $1, one year, split-adjusted
| Metric | BEAM | TARS |
|---|---|---|
| Price | $27.23 | $74.85 |
| Market cap | $2.81B | $3.50B |
| Today | −5.58% | +0.88% |
| 1 month | +11.6% | −0.8% |
| 6 months | −11.3% | +17.7% |
| Year to date | −1.8% | −8.6% |
| 1 year | +9.9% | +10.9% |
| Revenue growth (YoY) | −94.2% | +69.4% |
| Gross margin | 100.0% | 93.0% |
| Net margin | −25036.3% | −10.7% |
| P/E (TTM) | — | — |
| Price / sales | 18.0× | 5.8× |
| Net cash | $1.05B | $376.9M |
| Dividend yield | — | — |
| Volatility (60d) | 62.4% | 46.7% |
| Short % of float | 32.0% | 15.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).